PERICYTES AS TARGETS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA

Endpoints NewsLack of specifics on obesity pill sales hover over Lilly’s first quarter

Endpoints NewsThe R&D 15: How pharma's top companies spent, won and lost on drug research

Endpoints NewsNovartis unveils North Carolina factory as final new build in $23B US expansion

FierceBiotechGSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2

FierceBiotechAvalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

FierceBiotechAstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M

Novo NordiskIs Novo Nordisk's GLP-1 dominance fading after Lilly's clinical wins? - MSN

Siemens HealthineersSiemens Healthineers: A €6 Billion Diagnostics Exit and a Coming Spin-Off as Shares Hit Rock Botto - AD HOC NEWS

BioPharma DiveAvalyn, in pursuit of better lung drugs, banks $300M in an IPO

Sinopharm Chemical Reagent Co., Ltd.Stabilizers Price in China - Market Insights - IndexBox

eLifeThe FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycle

Insilico MedicineInsilico Medicine Secures IND Clearance For Rentosertib Inhalation Solution To Advance Targeted IPF Therapy - BioPharma APAC